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1. Partie de laboratoire 
Cette première étude décrit le développement et la validation, selon les standards 
internationaux, de deux techniques de mesure des concentrations sanguines de voriconazole, 
un nouvel agent antifongique à large spectre: 1) la chromatographie en phase liquide à haute 
pression et 2) le bio-essai utilisant une souche mutante de Candida hypersensible au 
voriconazole. Ce travail a aussi permis de mettre en évidence une importante et imprévisible 
variabilité inter- et intra-individuelle des concentrations sanguines de voriconazole malgré 
l'utilisation des doses recommandées par le fabriquant. Ce travail a été publié dans un journal 
avec "peer-review": "Variability of voriconazole plasma levels measured by new high-
performance liquid chromatography and bioassay methods" by A. Pascual, V. Nieth, T. 
Calandra, J. Bille, S. Bolay, L.A. Decosterd, T. Buclin, P.A. Majcherczyk, D. Sanglard, O. 
Marchetti. Antimicrobial Agents Chemotherapy, 2007,· 51: 137-43 
2. Partie Clinique 
Cette deuxième étude a évalué de façon prospective l'impact clinique des concentrations 
sanguines de voriconazole sur l'efficacité et sécurité thérapeutique chez des patients atteints 
d'infections fongiques. Des concentrations sanguines élevées étaient significativement 
associés à la survenue d'une toxicité neurologique (encéphalopathie avec confusion, 
hallucinations et myoclonies) et des concentrations sanguines basses à une réponse 
insuffisante au traitement antifongique (persistance ou progression des signes cliniques et 
radiologiques de l'infection). Dans la majorité des cas, un ajustement de la dose de 
voriconazole, sur la base des concentrations mesurées, a abouti à une récupération 
neurologique complète ou à une résolution de l'infection, respectivement. Ce travail a été 
publié dans un journal avec "peer-review": "Voriconazole Therapeutic Drug Monitoring in 
Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes" by A. Pascual, T. 
Calandra, S. Bolay, T. Buclin, J. Bille, and O. Marchetti. Clinicat Infectious Diseases, 2008 
January 15,· 46(2): 201-11. 
Ces deux études, financées de façon conjointe par un "grant" international de la Société suisse 
d'infectiologie et la Société internationale de maladies infectieuses et par la Fondation pour le 
progrès en microbiologie médicale et maladies infectieuses (FAMMID, Lausanne), ont été 
réalisées au sein du Service des Maladies Infectieuses, Département de Médecine, au CHUV, 
en étroite collaboration avec la Division de Pharmacologie Clinique, Département de 
Médecine, au CHUV et l'Institut de Microbiologi~ du CHUV et de l'Université de Lausanne. 
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Voriconazole (VRC) is a broad-spectrum antifungal triazole with nonlinear pharmacokinetics. The utility of 
measurement of voriconazole blood levels for optimizing therapy is a matter of debate. Available high-
performance liquid chromatography (HPLC) and bioassay methods are technically complex, time-consuming, 
or have a narrow analytical range. Objectives of the present study were to develop new, simple analytical 
methods and to assess variability of voriconazole blood levels in patients with invasive mycoses. Acetonitrile 
precipitation, reverse-phase separation, and UV detection were used for HPLC. A voriconazole-hypersuscep-
tible Candida albicans mutant lacking multidrug efHux transporters (cdrllJ../cdrlti, cdr2ti/cdr21J..,jiulti/fiulti, 
and mdrlti/mdrlti) and calcineurin subunit A (cnati/cnati) was used for bioassay. Mean intra-/interrun 
accuracies over the VRC concentration range from 0.25 to 16 mg/liter were 93. 7% ± 5.0%/96.5% ± 2.4% 
(HPLC) and 94.9% ± 6.1%/94.7% ± 3.3% (bioassay). Mean intra-/internm coefficients of variation were 5.2% ± 
1.5%/5.4% ± 0.9% and 6.5% ± 2.5%/4.0% ± 1.6% for HPLC and bioassay, respectively. The coefficient of 
concordance between HPLC and bioassay was 0.96. Sequential measurements in 10 patients with invasive 
mycoses showed important inter- and intraindividual variations of estimated voriconazole area under the 
concentration-time curve (AUC): median, 43.9 mg· h/liter (range, 12.9 to 71.1) on the first and 27.4 mg· h/liter 
(range, 2.9 to 93.1) on the last day of therapy. During therapy, AUC decreased in five patients, increased in 
three, and remained unchanged in two. A toxic encephalopathy probably related to the increase of the VRC 
AUC (from 71.1 to 93.l mg· h/liter) was observed. The VRC AUC decreased (from 12.9 to 2.9 mg· h/liter) in 
a patient with persistent signs of invasive aspergillosis. These preliminary observations suggest that voricon-
azole over- or underexposure resulting from variability of blood levels might have clinicat implications. Simple 
HPLC and bioassay methods oll'er new tools for monitoring voriconazole therapy. 
Voriconazole (VRC) is a new treatment option for aspergil-
losis, candidiasis, other emerging or refractory mycoses, and 
persistent fever during neutropenia (1, 4, 6, 8, 12, 15, 22, 25, 
36). Combinations of VRC with other antifungal agents are 
being investigated for use with severe infections (3, 21). A 
correlation between in vitro MIC of VRC and response to 
antifungal therapy has been described previously (26). The 
VRC area under the concentration-time curve (AUC)/MIC 
ratio is the pharmacokinetic/-dynamic parameter which best 
predicts success in experimental candidiasis (2). Nonlinear 
pharmacokinetics, genetic polymorphism of the cytochrome 
P450 enzyme CYP2Cl9, changes in volume of distribution, 
drug interactions, hepatic dysfunction, and age may modify 
VRC pharmacokinetics (10, 13, 14, 16, 28). Interindividual 
variability of VRC blood levels has been reported previously, 
but it is unclear whether intraindividual variations also occur 
during therapy (10). VRC blood levels of <0.5 mg/liter (MIC90 
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for Candida and Aspergillus spp.) have been observed in 20% 
of patients with invasive aspergillosis (10). VRC trough blood 
concentrations of <0.25 mg/liter have been reported for chil-
dren (35). Denning et al. described treatment failures in pa-
tients with VRC plasma concentrations of <0.25 mg/liter (6). 
VRC blood levels as high as 15 mg/liter were observed for 
subjects with liver toxicity or a "poor metabolizer" CYP2Cl9 
genotype (5-7, 10, 14, 27). Whether measurement of VRC 
blood levels may optimize therapy in individual patients is a 
matter of debate (7). 
Reported high-performance liquid chromatography (HPLC) 
methods are characterized by complex extraction, long analyt-
ical time, or limited analytical range (11, 23, 24, 34). A bioassay 
method using Candida kefYr ATCC 46764 (VRC MIC, 0.015 
mg/liter) has been validated over a range of 0.8 to 3.6 mg/liter 
(24). Clinical observations suggest that quantification of VRC 
blood levels between 0.25 and 15 mg/liter is needed. Azole-
hypersusceptible C. albicans mutants constructed by targeted 
deletion of genes encoding multidrug effiux transporters and 
calcineurin offer interesting tools for development of bioassays 
(19, 20, 31 ). The objectives of this study were to develop simple 
HPLC and bioassay methods with a clinically relevant analyt-
ical range and to assess the variability of VRC blood levels by 
sequential measurements in patients with invasive mycoses. 
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(Part of the study was presented at the 44th Interscience 
Conference on Antimicrobial Agents and Chemotherapy, 30 
October to 2 November 2004, Washington, DC.) 
l.YIATERIALS AND METHODS 
HPLC. (i) Sample preparation. Pive hundred microliters of plasma and 500 µl 
of acetonitrile (Merck, Darmstadt, Germany) were vortexed/mixed (10 s), stored 
at 4°C (10 min), and centrifuged at 17,900 X g (5 min). The supernatant (500 µl) 
was transferred into an Eppendorf tube and evaporated under nitrogen stream (1 
h) (nitrogen dryer; bioMérieux, Marcy !'Etoile, France). The dry residue was 
reconstituted in 200 µl of ultrapure water (Direct-Q water system; Millipore, 
Bedford, MA). 
(ii) System. The HPLC system (Hitachi Instruments, Ichige, Hitachinaka, 
Japan) consisted of an L-2200 Peltier autosampler, an L-2100 gradient pump 
(with low-pressure mixing), and an L-2450 diode array detector. The results were 
analyzed using EZChrom Elite software, version 3.1 (Hitachi Instruments, 
Tokyo, J apan). 
(iii) Conditions. Samples were maintained at 4'C in the autosampler prior ta 
injection, and the column temperature was maintained at 35°C. Fifty-microliter 
samples were injected and separated using a reverse-phase C18 column (Nucleo-
sil 300-5, C18, 15 cm by 4.6 mm; Macherey-Nagel, Oensingen, Switzerland) with 
a universal security guard cartridge (Macherey-Nagel, Oensingen, Switzerland), 
an isocratic gradient of 50% (vol/vol) methanol (Merck, Dietikon, Switzerland) 
in 0.01 M sodium acetate buffer, pH 5.0 (Merck, Dietikon, Switzerland), and a 
flow rate of the mobile phase of 1.0 ml/min. The eluent was monitored al a 
255-nm wavelength (deuterium lamp; Hamamatsu Photonics, Toyooka, Japan) 
and absorbance measured in arbitrary units. 
(iv) Analysis. Bach analytical run included one blank, eight standards, and four 
quality contrai samples (see paragraph i in "Validation of HPLC and bioassay" 
section). Ail samples were analyzed in duplicate. The amount of VRC was 
calculated by an externat standard method based on peak are as ( see paragraph 
iii in "Validation of HPLC and bioassay" section). 
Bioassay. (i) Strains. C. albicans mutant DSY2621 was constructed by targeted 
deletions of genes encoding membrane effiux transporters (cdrll'i::hisG/cdrll'i:: 
hisG, cdr21'i::hisG/cdr2/'i::hisG, flull'i::hisG!flull'i::hisG, and mdrl ù::hisG/ 
mdrlù::hisG) and calcineurin subunit A (cnaù::hisG/cnaù::hisG-URA3-hisG) 
(VRC MIC, 0.008 mg/liter) (31). C. albicans ATCC 95020 (VRC MIC, 0.015 
mg/liter) and C. kefyr B11501, a clinicat isolate from the collection of the micro-
biology laboratory of our hospital (VRC MIC, 0.015 mg/liter), were also used. 
Strains were maintained at 4'C on Sabouraud dextrose agar plates (Difco Lab-
oratories, Base!, Switzerland). 
(ii) Inoculum. A single CFU of the test strain was grown overnight under 
agitation (214 rpm) at a temperature of 35°C in 2 ml of yeast extract-peptone-
dextrose medium (10 g/liter Bacto peptone [Difco Laboratories, Base!, Switzer-
land], 5 g/liter yeast extract [Difco Laboratories, Base!, Switzerland], and 20 
g/liter glucose [Fluka, Steinheim, Switzerland]). An inoculum of 1.5 X 107 
CFU/ml was prepared by diluting the overnight culture with 0.9% NaCl ta an 
optical density of 0.4 arbitrary units of absorbance at a wavelength of 540 nm 
(Novaspec II; Pharmacia Biotech, Cambridge, England). The viable counts of 
the inoculum were determined by subcultures on Sabouraud dextrose agar 
plates. 
(iii) Medium and agar plate. A broth medium (412.5 ml) containing 25 g/liter 
agar (Becton Dickinson, Sparks, MD) and 8 g/liter ofyeast nitrogen base (Becton 
Dickinson, Sparks, MD) was autoclaved and then allowed ta equilibrate al a 
temperature of 50'C. Fifty milliliters of a 20% glucose aqueous solution was 
added (Sigma-Aldrich Chemie, Steinheim, Germany). A buffer solution (12.8 
ml) (7.15 g KH2P04 [Sigma-Aldrich Chemie, Steinheim, Germany] and 50 g 
Na2HP04 · 2H20 [Merck, Darmstadt, Germany] diluted in 500 ml of bidistilled 
water with a final pH of 5.5), 115 ml of broth medium, and 2.6 ml of inoculum 
were mixed at a temperature of 50°C. The final volume of 130.4 ml was poured 
into a square glass plate (220 by 220 mm). The agar was allowed ta solidify at 
room temperature. Thereafter, 16 round wells (diameter, 4 mm; capacity, 25 µl) 
were eut using a sterile cork borer over a standard template. Bach well was filled 
with 25 µl of plasma, which was allowed ta diffuse through the agar at 4 'C for 2 h. 
The plate was then incubated at 35°C for 14 h. 
(iv) Analysis. Bach analytical run included the following plasma samples in 
duplicate: one blank, eight standards, and four quality contrais. Growth inhibi-
tion around wells was quantified by measuring the horizontal, the vertical, and 
the Iwo diagonal diameters ta the nearest 0.1 mm with a Vernier caliper. The 
amount of VRC was calculated by an externat standard method (see paragraph 
iii in "Validation of HPLC and bioassay" section). 
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Validation of HPLC and bioassay. HPLC and bioassay were internally vali-
dated over a concentration range of 0.25 ta 16 mg/liter according ta the inter-
national recommendations for analytical method validation (9, 32). 
(i) Spiked plasma samples. Citrated plasma from healthy donors was kindly 
supplied by the blood transfusion service of our hospital. A batch of spiked 
human plasma samples was prepared from an aqueous stock solution containing 
1 mg/liter of VRC. VRC pure substance was kindly supplied by Pfizer Central 
Research (Sandwich, United Kingdom). Eight standards (i.e., samples used ta 
calculate a regression equation) were obtained by serial dilutions: 0.19, 0.39, 0.78, 
1.56, 3.12, 6.25, 12.5, and 25 mg/liter. The four quality contrai samples (i.e., used 
for back calculation of VRC values by the regression equation) contained 0.25, 
1, 4, and 16 mg/liter. Aliquots of each concentration were prepared for HPLC 
(500 µ!)and bioassay (60 µl) and frozen at -80°C. Spiked plasma samples from 
a unique batch were used for the entire validation procedure. 
(ii) Limits of detection and quantification. The limit of detection (LOD) was 
defined as the lowest VRC concentration that could be differentiated reliably 
from background noise (mean of 12 different background noise measurements ± 
3 standard deviations for HPLC) or could be recognized as a delimited zone of 
growth inhibition (for bioassay). The limit of quantification (LOQ) was defined 
as the lowest amount of VRC that could be quantified in a plasma sample with 
±20% accuracy and precision (9, 32). 
(iii) Standard curves. Curves consisting of eight points (0.2 ta 25 mg/liter) 
were calculated by linear regression (best fit obtained by exploring different 
weighting factors when plotting peak areas measured by HPLC against VRC 
concentrations) or by quadratic regression (best fit obtained by plotting diame-
ters of growth inhibition measured by bioassay against VRC concentrations). 
(iv) Recovery of VRC from plasma. The absolute recovery of VRC from 
plasma (biological matrix) was calculated for the four quality contrai samples as 
follows: measured concentration in plasma/measured concentration in water X 
100. Ta assess the efficiency of VRC extraction from plasma, a 50-µl volume of 
water spiked with VRC was injected into the HPLC ( equaling 100% recovery); 
percent recovery of VRC from extracted plasma was calculated according ta the 
formula given above. 
(v) Influence of the anticoagulant on VRC quantification. The percentages of 
measured/nominal VRC values in quality contrai samples were compared in 
plasma containing citrate, heparin, or EDTA and in serum. Citrated standard 
plasma samples were used for the calibration cu1ve. 
(vi) Quantification ofVRC over lime under different storage conditions. Qual-
ity controls were tested for stability of VRC over lime (percent deviation of 
measured from initial values) (a) in plasma at 4 and 21'C (7 days), (b) in plasma 
at -80°C (12 months), and (c) in plasma during four freeze-thaw cycles. Stability 
was also measured in whole blood from a patient treated with VRC at 4 and 21 'C 
(7 days). 
(vii) Accuracy and precision. Intra- and interrun accuracy (measured value/ 
nominal value X 100) and precision [(coefficient of variation) = (standard 
deviation/mean of measured values X 100)] were assessed for the four quality 
contrais with six duplicate measurements within the same experiment or in six 
experiments (each with duplicate measurements) performed on different days, 
respectively. 
(viii) Selectivity. Ta assess the selectivity of the HPLC method for VRC, the 
following antifungals, antibiotics, antivirals, and immunosuppressants were tested 
with VRC: (a) amphotericin B, caspofungin, 5-flucytosine, fluconazole, and itra-
conazole; (b) amoxicillin-clavulanic acid, piperacillin-tazobactam, cefepime, ceftazi-
dime, ceftriaxone, imipenem, meropenem, teicoplanin, vancomycin, clindamycin, 
clarithromycin, ciprofloxacin, levofloxacin, metronidazole, trimethoprim, amikacin, 
gentamicin, and rifampin; (c) amprenavir, efavirenz, indinavir, lopinavir, nelfinavir, 
nevirapine, saquinavir, and ritonavir; and (d) cyclosporine A and tacrcilimus. 
(ix) Concordance between HPLC and bioassay. The agreement between VRC 
levels measured by HPLC and bioassay in plasma samples from patients treated 
with VRC was analyzed by a method proposed by Lin (17). Measurements by 
HPLC and bioassay were performed by two different investigators who were 
blinded of the results obtained with the other method. The coefficient of con-
cordance was calculated using the following parameters: µ 1 and µ,, means of 
values measured by HPLC and bioassay; CJ 1 and CJ2, standard deviations of values 
measured by HPLC and bioassay; location shift (u), (µ. 1 - µ 2)/y(CJ1 - CJ2); scale 
shift (v), CJ1/CJ2; precision (r), coefficient of correlation; congruence (A), [(v + 1/v + 
µ.2)12r1; concordance, r x A. 
Measurements of VRC blood levels in patients \VÏ!h invasive mycoses. Inpa-
tients receiving VRC therapy in the ward of the Infections Diseases Service over 
a 9-month period were studied after providing written informed consent. The 
study protocol was approved by the Institutional Ethical Committee. VRC load-
ing and maintenance doses followed manufacturer's recommendations. Clinicat 
data on demographics, diagnosis of fungal infection (according ta EORTC/MSG 
VOL. 51, 2007 V ARIABILITY OF VORICONAZOLE LEVELS BY HPLC/BIOASSA Y 139 
TABLE 1. Intra- and interrun validation of the HPLC method and the bioassay"·" 
HPLC Bioassay 
Nominal VRC Intrarun (n = 6) Interrun (11 = 6) Intrarun (11 = 6) Interrun (n = 6) 
concn(s) 
(mg/liter) Accuracy" Coefficient of Accuracy Coefficient of Accuracy Coefficient of Accuracy Coefficient of 
(%) variationc (%) (%) variation (%) (%) variation (%) (%) variation (%) 
0.25 100.7 ± 6.4 6.4 98.9 ± 4.2 5.1 89.0 ± 4.1 5.0 90.9 ± 3.6 4.2 
1 89.8 ± 3.5 3.9 93.2 ± 5.6 6.3 99.2 ± 10.2 10.3 96.3 ± 5.8 6.1 
4 90.1 ± 6.0 6.6 96.2 ± 5.9 5.9 96.6 ± 5.0 5.2 97.8 ± 2.1 2.2 
16 94.3 ± 3.6 3.9 97.5 ± 5.0 4.3 94.7 ± 5.2 5.5 93.9 ± 1.7 3.6 
Ali 93.7 ± 5.0 5.2 ± 1.5 96.5 ± 2.4 5.4 ± 0.9 94.9 ± 6.1 6.5 ± 2.5 94.7 ± 3.3 4.0 ± 1.6 
"The bioassay method used the C. albicans mutant lacking four multidrug efllux transporters (cdrlD./cdrlD., cdr2t;./cdr2D.,flult;./flu1D., and mdrlt;./mdrlD.) and the 
calcineurin subunit A (cnat;./cnaD.). 
b The accuracy was calculated as follows: measured concentration/nominal concentration X 100. 
c The coefficient of variation was calculated as follows: standard deviation of measured concentration/mean measured concentration X 100. 
d Mean values ± standard deviations are shown. 
criteria), response to therapy (complete or partial clinical/radiological resolution 
or persistent signs of infection), comedications, and adverse events (according to 
National Cancer Institute grading criteria) were prospectively collected. VRC 
blood levels were measured on days 2, 7, and 14 of antifungal therapy. Two 
milliliters of citrated blood was drawn just before and 2, 4, 6, and 12 h after VRC 
administration. VRC levels were measured by HPLC as described above. Aver-
age exposure to VRC was assessed by the estimated AUC over one dosing 
interval (0 to 12 h) calculated by the linear trapezoidal rule during increase and 
the log trapezoidal rule during decay (29). VRC peak concentrations in serum 
(C0,,L,), trough concentrations, and estimated AUC values were analyzed by 
descriptive statistics. 
RESULTS 
HPLC. A plasma peak overlapping with that of VRC at a 
retention time of 8 min was observed using a recently reported 
HPLC method (24). The effect was independent from the type 
of organic matrix and occurred in plasma containing citrate, 
heparin, or EDTA and in serum. To eliminate this interfer-
ence, we modified the experimental conditions by using a dif-
ferent mobile phase (50/50 [vol/vol] methanol and sodium ac-
etate) and a shorter column (C18, 150 by 4.6 mm, 5 µm). The 
run time was significantly shorter (12 min), and the chromato-
gram showed a VRC peak free of interferences after a reten-
tion time of 7.4 min regardless of the type of biological matrix 
(plasma with different anticoagulants or serum). 
For the standard curve, a linear regression with a 1/x2 
weighting factor was used ( sum of the relative errors by back 
calculation of the VRC concentrations in standards, 2.9%; 
range of relative errors, 0.4 to 5.9%; constant variability of 
relative errors over the analytical range, 0.125 to 25 mg/liter). 
The mean curve parameters were as follows: a = 287,048 :±: 
27,801; b = -4,816 :±: 7,372; r2 = 0.0997 :±: 0.002. The LOD 
and LOQ of VRC were 0.04 and 0.125 mg/liter, respectively. 
The absolute VRC recovery was 102% :±: 6%. The influence of 
the biological matrix on VRC quantification was studied. The 
mean percent ratios of measured/expected VRC values in 
plasma containing citrate, heparin, or EDTA and in serum 
were 93.7% :±: 5.0%, 87% :±: 1.6%, 89.1 % :±: 5.7%, and 
91.9% :±: 1.9%, respectively. The quantifications over time of 
VRC in stored plasma (measured values/initial values X 100) 
were 95% :±: 4% and 94% :±: 3% at 4 and 21°C, respectively, 
over 7 days, 98% :±: 9% at -80°C over 12 months, and 95% :±: 
7% after four freeze-thaw cycles. The ratios (measured values/ 
initial values X 100) in whole blood drawn from patients 
treated with VRC and stored over 4 days were 92% :±: 4% at 
4°C and 95% :±: 6% at 21°C. 
Table 1 summarizes the results of intrarun and interrun 
validations over the 0.25- to 16-mg/liter concentration range. 
The mean intrarun accuracy was 93.7% :±: 5.0%, and the mean 
coefficient of variation was 5.2% :±: 1.5%. The mean interrun 
accuracy was 96.5% :±: 2.4%, and the mean coefficient of vari-
ation was 5.4% :±: 0.9%. 
To assess the selectivity of the HPLC method, the retention 
times of the commonly used antifungals (n = 5), antibiotics 
(n = 18), antivirals (n = 8), and immunosuppressive drugs 
(n = 2) listed in Materials and Methods were studied. The 
antiretroviral agents indinavir and amprenavir had retention 
times overlapping with that of VRC, leading to potential in-
terferences with calculation of the VRC concentrations. No 
interference was observed between VRC and the remaining 
drugs. 
Bioassay. VRC bioassays using the azole-hypersusceptible 
C. albicans mutant (cdrl!:i./cdrll:., cdr2!:J./cdr2!:J., fiul!:i./flul!:J., 
mdrl!:J./mdrl!:J., and cna!:i./cna!:J.), the reference strain C. albi-
cans ATCC 95020, and the clinical isolate C. kefyr B11501 were 
compared. The zones of growth inhibition of the standard 
curve obtained with the hypersusceptible C. albicans mutant 
were well delimited and ranged between 17 and 52 mm over 
the 0.2- to 25-mg/liter VRC concentration analytical range. 
Those obtained with C. albicans ATCC 95020 and C. kefyr 
B11501 ranged between 21 and 39 mm and between 23 and 39 
mm, respectively. The LOD and LOQ of the methods using the 
azole-hypersusceptible C. albicans mutant were 0.1 mg/liter 
and 0.2 mg/liter, respectively, and those with C. albicans ATCC 
95020 or C. kefyr B11501 were 0.39 mg/liter and 0.5 mg/liter, 
respectively. With the hypersusceptible mutant, excellent stan-
dard curve reproducibility was obtained ( mean :±: standard 
deviation): b0 = -1.92 :±: 0.42, b1 = 0.04 :±: 0.02, b2 = 0.0007 :±: 
Q.0003, and 12 = 0.998 :±: 0.035. The influence of the biological 
matrix on VRC quantification was studied. The absolute VRC 
recovery was 99% :±: 0.5%. The mean percent ratios of mea-
sured/nominal VRC values in plasma containing citrate, hep-
arin, or EDTA and in serum were 97.6% :±: 3.6%, 95.4% :±: 
1.4%, 95.4% :±: 1.4%, and 106.3% :±: 3.7%, respectively. The 
quantifications over time of VRC in stored plasma (measured 
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FIG. 1. Scatter plot of plasma VRC levels measured by HPLC and 
bioassay using the C. albicans mutant (cdrl!:i/cdrl!:i, cdr21:!./cdr21:!., 
fful!:i/fful!:i, mdrl !:i/mdrl!:i, and cna!:i/cna!:i). The line of congruence 
does not deviate from 1. The coefficient of concordance is 0.96. 
values/initial values X 100) were 99% ± 3% and 99% ± 3% at 
4 and 21°C, respectively, over 7 days, 99% ± 5% at -80°C over 
12 months, and 104% ± 4% after four freeze-thaw cycles. The 
ratios (measured values/initial values X 100) in whole blood 
drawn from patients treated with VRC and stored over 4 days 
were 99% ± 1% at 4°C and 99% ± 0.5% at 21°C. 
The intra-/interrun accuracy (mean, 94.9% ± 6.1 %/94.7% ± 
3.3%) and precision (mean coefficients of variation, 6.5% ± 
2.5%/4.0% ± 1.6%) were well within the recommended vali-
dation limits (accuracy, 85% to 115%, and precision, ±15%) 
(Table 1) (9, 32). 
Concordance between HPLC and bioassay. The comparison 
of the VRC levels measured in 58 clinical plasma samples by 
HPLC and bioassay methods handled by different laboratory 
technicians is shown in Fig. 1. The correlation coefficient was 
0.97 (P < 0.001), and the coefficient of concordance calculated 
according to the method reported by Lin (17) was 0.96 (u 
[location shift], 0.007; v [scale shift], 1.283; A [congruence], 
0.99). 
Measurements ofVRC blood levels in patients with invasive 
mycoses. Ten Caucasian adult patients were studied (Table 2). 
None had underlying hepatic or renal disease. During the 
study period, VRC dosing schedules remained unchanged. 
VRC blood levels were measured over 7 days of therapy in 
five patients and over 14 days in the remaining five. In seven 
cases, the study ended at discharge from the hospital. In three 
cases, VRC therapy was discontinued after invasive mycosis 
was ruled out (one case), because of a se rio us adverse event 
(one case), or because of persistent signs of infection requiring 
a switch to a salvage regimen (one case). 
The median Cmax values were 6 mg/liter (range, 2.7 to 6.4) 
on the first day and 3.8 (range, 0.3 to 8.2) on the last day of 
study. The median VRC trough levels were 3 (range, 0.3 to 5.6) 
and 1.2 (range, 0.2 to 7.4), respectively. Average exposure was 
expressed by estimated AUC based on measurements of VRC 
blood levels at three to five time points. The median estimated 
VRC AUC value decreased over the study period from 43.9 
mg· h/liter (range, 12.9 to 71.1) to 27.4 mg· h/liter (range, 2.9 
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to 93.1). In five patients, the AUC value decreased (19.9%, 
38.3%, 52.9%, 40.9%, and 77.5% ). One patient was treated 
with VRC intravenously (i.v.), two orally, and two had an 
intravenous-to-oral switch with identical VRC daily doses; two 
patients received concomitant medication with esomeprazole 
and one with imatinib. In three cases, the VRC AUC increased 
(30.6%, 30.9%, and 107.1 % ). Two patients were treated with 
VRC i.v., and one had an intravenous-to-oral switch with no 
change of the VRC daily dose; one patient received esome-
prazole comedication. The VRC AUC remained unchanged in 
two cases ( decreased 5.8% and 9.9% ): one patient was treated 
with VRC orally, and one had an intravenous-to-oral switch 
with the same VRC daily dose. 
Figure 2 shows the course of the estimated VRC AUC 
values during the study period in the 10 patients (Fig. 2A) and 
three individual VRC concentration-time curves (Fig. 2B to 
D). A leukemic patient with proven pulmonary aspergillosis 
and increasing VRC exposure (at day 2, Cmax was 6.4 mg/liter, 
trough was 5.6 mg/liter, and AUC was 71.1 mg · h/liter; at day 
7, Cmax was 8.2 mg/liter, trough was 7 mg/liter, and AUC was 
93.1 mg · h/liter) under 200 mg orally twice daily developed a 
taxie encephalopathy (confusion, agitation, and hallucinations; 
grade 3 according to NCI classification) and a mild cholestasis 
( alkaline phosphatase three times the upper normal value) 
(Fig. 2B). This adverse event was probably related to high 
VRC blood levels and promptly resolved after interruption of 
therapy. The comedication with esomeprazole may have inter-
acted with VRC metabolism and contributed to the increase of 
VRC exposure. Rechallenge with lower VRC doses (150 mg 
twice daily) was well tolerated. A persistence of signs of prob-
able pulmonary aspergillosis (persistent fever and inflamma-
TABLE 2. Characteristics of 10 patients treated with VRC 
Characteristic 
No. of 
patients with 
characteristic 
Gender ( male/female )" ............................................................................... 8/2 
Underlying conditions 
Acute leukemia/neutropenia after 
myeloablative chemotherapy .......................................................... 8 
None .......................................................................................................... 2 
VRC therapy 
Indications 
Invasive aspergillosis ........................................................................... 7 
Proven/probable ............................................................................... 4/3 
Pulmonary/rhinocerebral/disseminated ......................................... 5/1/1 
Possible pulmonary invasive mycosis ................................................ 2 
Persistent fever during neutropenia .................................................. 1 
Settings 
First-line therapy ................................................................................. 4 
Salvage therapy (failure of/intolerance ta 
previous antifungal therapy) .......................................................... 4 (2/2) 
Intravenous-to-oral switch after therapy 
with another antifungal agent.. ...................................................... 2 
Initial route of administration (i.v./oraJY' ............................................ 8/2 
Intravenous-to-oral switch during VRC therapy ............................. 4 
-Response of infection ta antifungal therapy on 
day 14 (complete response/partial 
response/persistence of infection) ................................................. 2/6/2 
Adverse event leading ta discontinuation of therapy ......................... 1 
"The median patient age was 62 years (range, 28 ta 64 years ), and the median 
patient weight was 69 kg (range, 50 ta 98 kg). 
b The median dose, given twice daily, was 4 mg/kg of body weight (range, 2.5 
ta 4.6 mg/kg). 
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tory syndrome, radiological progression of the initial focus, and 
documentation of a new contralateral pulmonary lesion) was 
observed during the neutropenic period in a leukemic patient 
receiving 200 mg orally twice daily. A drop in VRC blood levels 
was documented (at day 7, cmax was 1.9 mg/liter, trough was 
0.5 mg/liter, and AUC was 12.9 mg · h/liter; at day 14, Cmax was 
0.3 mg/liter, trough was 0.2 mg/liter, and AUC was 2.9 mg · 
h/liter) (Fig. 2C). No cause for the decrease of VRC exposure 
was identified: the dose had remained unchanged, no comedi-
cation interacting with VRC metabolism had been added, and 
drug compliance was appropriate. A clinical and radiological 
resolution of the infection was obtained after increase of the 
VRC dose to 300 mg orally twice daily. In another leukemic 
neutropenic patient, persistent signs of probable pulmonary 
aspergillosis (persistent fever, increasing inftammatory syn-
drome, and radiological progression of multiple pulmonary 
lesions) were observed. With a VRC dose of 300 mg orally 
twice daily, VRC Cmax and trough levels at the time of assess-
ment of persistence of infection were 4.3 and 2.6 mg/liter, 
respectively (AUC had remained unchanged, i.e., 43 mg · h/li-
ter on the first day and 40.5 mg · h/liter on the last day of 
therapy). In this patient, therapy was switched to a salvage 
regimen with liposomal amphotericin B and a complete reso-
lution of infection was obtained. Figure 2D shows stable con-
centration-time curves from a leukemic patient with an un-
eventful clinical course. 
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DISCUSSION 
Reported HPLC methods for measurement of VRC b\ood 
levels are technically complex and/or time-consuming ( e.g., 
extraction procedure of >4 h and/or run time of >30 min) (11, 
23, 24, 34). With a recently described method using organic 
phase extraction, we have observed a peak interfering with the 
VRC quantification (24). The reported C. kefyr ATCC 46764 
bioassay bas a limited analytical range (0.8 to 3.6 mg/liter) (24) . 
The present study reports the development of new, simple 
HPLC and bioassay methods with an analytical performance 
meeting clinical requirements. 
Plasma VRC extraction by acetonitrile precipitation fol-
lowed by evaporation under nitrogen stream and reverse-phase 
FIG. 2. (A) Courses of estimated VRC AUC in 10 patients. (B to 
D) Individual VRC concentration-time curves. (B) Patient with proven 
pulmonary aspergillosis, taxie encephalopathy, and mild cholestasis. 
Increasing VRC blood levels were observed (Ll.AUC + 30.9%) despite 
an unchanged VRC dose (200 mg orally twice daily; a switch from i.v. 
to oral treatment had occurred). During the entire study period, the 
patient received esomeprazole. This serious neurological adverse event 
was probably related to VRC overdosing and completely resolved after 
stop of VRC therapy. Rechallenge with lower VRC doses (150 mg 
orally twice daily) was well tolerated. (C) Patient with persistent signs 
of probable pulmonary aspergillosis. Decreasing VRC exposure was 
documented (Ll.AUC - 77.5%) despite an unchanged VRC dose (200 
mg orally twice daily) and absence of comedication interacting with 
VRC metabolism. The infection responded after increase of the VRC 
dose to 300 mg orally twice daily. (D) Patient with probable pulmonary 
aspergillosis and an uneventful clinicat course. VRC concentrations 
were stable (Ll.AUC - 9.9%). The VRC dose was 300 mg twice daily, 
the route was i.v. on days 2 and 7, and there was no comedication 
interacting with VRC metabolism. 
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separation followed by UV detection over 12 min were used 
for HPLC. The absolute recovery of VRC from plasma was 
close to 100%. The method has been validated according to 
international guidelines over the 0.25- to 16-mg/liter analytical 
range, which covers the clinically relevant concentration spec-
trum (5-7, 10, 14, 27, 35). Results are not influenced by type of 
organic matrix or anticoagulant and are reproducible under 
different storage conditions. The technique selectively detects 
VRC in the presence of a large number of frequently used 
antimicrobial and immunosuppressive drugs: analytical inter-
ferences have been observed only with the antiretroviral agents 
indinavir and amprenavir. Simple preanalytical processing and 
short analytical time (results available within 6 h) are advan-
tages of this HPLC technique over those previously reported. 
The new bioassay uses an azole-hypersusceptible C. albicans 
mutant constructed by targeted deletion of genes encoding 
multidrug effiux transporters and calcineurin subunit A (31). 
This simple test using very small volumes of plasma (50 µ!,i.e., 
10 times lower that those needed for HPLC) has an analytical 
range identical to that of HPLC (0.25 to 16 mg/liter). The 
concordance between VRC levels measured in clinical plasma 
samples by HPLC and bioassay was excellent. Despite a longer 
analytical time (16 h), bioassay may be a valid alternative to 
HPLC. Bioassay is particularly useful for analyses with small 
volumes of blood ( e.g., from children), when analytical inter-
ferences alter detection of VRC by HPLC, or in laboratories 
not equipped for HPLC. 
Multiple factors have been associated with interindividual 
variations of VRC blood levels (10, 13, 16, 28, 37). Decrease of 
VRC blood levels during therapy has been reported in exper-
imental models with rats, mice, and dogs (30). Autoinduction 
of cytochrome P450 metabolism by VRC has been associated 
with this phenomenon. It is unclear whether intraindividual 
variations also occur in humans (10, 16, 28). The utility of 
measuring VRC blood levels to improve clinical management 
has been a matter of debate in recent reports (5-7, 10, 18, 27, 
33, 35). We sequentially measured VRC blood levels in 
Caucasian adult patients receiving standard doses of VRC for 
invasive mycoses. Large inter- and intraindividual variations of 
VRC blood levels were observed. During the study period, 
VRC exposure decreased or increased in 8 out of 10 patients 
despite the absence of changes in VRC doses and of comedi-
cations interacting with VRC metabolism or liver fonction. 
Although oral bioavailability of VRC is excellent, an intrave-
nous-to-oral switch might have influenced VRC blood levels in 
some patients (10, 16, 28). Three clinical cases were illustrated. 
The first patient received esomeprazole as comedication and 
developed a toxic encephalopathy probably related to increas-
ing VRC exposure (Cmax level, 8.2 mg/liter; trough level, 7 
mg/liter; AUC, 93.1 mg · h/liter), which completely resolved 
after interruption of therapy. Rechallenge with lower doses of 
VRC was well tolerated. In a second neutropenic patient with 
persistent clinical and radiological signs of a probable invasive 
aspergillosis, a decrease in VRC blood levels and AUC (Cmax 
level, 0.3 mg/liter; trough level, 0.2 mg/liter; AUC, 2.9 mg · 
h/liter) was observed. No cause of this drop in VRC exposure 
was identified. Infection responded after increase of the VRC 
dose. In a third leukemic patient, persistence of a possible 
pulmonary mycosis despite appropriate VRC blood levels re-
quired a switch to a salvage therapy. In the remaining seven 
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patients, the clinical course was uneventful. These preliminary 
observations suggest that, in addition to interindividual differ-
ences, important intraindividual variations of VRC blood lev-
els may occur during therapy. Small sample size and lack of 
data on genetic polymorphism of CYP2C19 are important lim-
itations of this study. Nevertheless, in addition to those previ-
ously reported by other investigators, our clinical data suggest 
that VRC over- or underexposure might be associated with 
toxicity or persistence of infection, respectively. Simple, accu-
rate, and precise HPLC and bioassay techniques offer new 
tools for monitoring VRC therapy. 
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Voriconazole Therapeutic Drug Monitoring 
in Patients with Invasive Mycoses Improves 
Efficacy and Safety Outcomes 
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(See the editorial commentary by Lewis on pages 212-4) 
Background. Voriconazole is the therapy of choice for aspergillosis and a new treatment option for candidiasis. 
Liver disease, age, genetic polymorphism of the cytochrome CYP2Cl9, and comedications influence voriconazole 
metabolism. Large variations in voriconazole pharmacokinetics may be associated with decreased efficacy or with 
toxicity. 
Methods. This study was conducted to assess the utility of measuring voriconazole blood levels with individ-
ualized dose adjustments. 
Results. A total of 181 measurements with high-pressure liquid chromatography were performed during 2388 
treatment days in 52 patients. A large variability in voriconazole trough blood levels was observed, ranging from 
~ 1 mg/L (the minimum inhibitory concentration at which, for most fungal pathogens, 90% of isolat es are 
susceptible) in 25% of cases to >5.5 mg/L (a level possibly associated with toxicity) in 31 % of cases. Lack of 
response to therapy was more frequent in patients with voriconazole levels ~l mg/L (6 [46%] of 13 patients, 
including 5 patients with aspergillosis, 4 of whom were treated orally with a median dosage of 6 mg/kg per day) 
than in those with voriconazole levels >l mg/L (15 [12%] of 39 patients; P = .02). Blood levels >l mg/L were 
reached after increasing the voriconazole dosage, with complete resolution of infection in all 6 cases. Among 16 
patients with voriconazole trough blood levels >5.5 mg/L, 5 patients (31 %) presented with an encephalopathy, 
including 4 patients who were treated intravenously with a median voriconazole dosage of 8 mg/kg per day, whereas 
none of the patients with levels ~5.5 mg/L presented with neurological toxicity (P = .002 ). Comedication with 
omeprazole possibly contributed to voriconazole accumulation in 4 patients. In all cases, discontinuation of therapy 
resulted in prompt and complete neurological recovery. 
Conclusions. Voriconazole therapeutic drug monitoring improves the efficacy and safety of therapy in severely 
ill patients with invasive mycoses. 
Voriconazole is the first choice therapy for invasive as-
pergillosis and is a new treatment option for candidi-
asis, other emerging invasive fungal infections (IFI), 
such as fusariosis, and refractory IFI [1-5]. Status of 
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the hast immunity, localization and extension of in-
fection, early start of antifungal therapy, lack of re-
sponse to previous therapy, surgical management, and 
in vitro antifungal susceptibility of the pathogen are 
key determinants for a successful response [6-9]. The 
role of antifungal drug blood concentrations with re-
spect to efficacy and safety is unclear. Liver metabolism 
plays a key role in the disposition of voriconazole, 
which acts simultaneously as a substrate and inhibitor 
of multiple enzymes of the cytochrome P450 system 
[7]. Multiple factors have been found to be associated 
with a large variability in voriconazole exposure fol-
lowing standard dose administration, such as nonlinear 
saturable pharmacokinetics, drug-drug interactions, 
liver disease, patient age (in particular, with respect to 
children), and genetic polymorphism of the cyto-
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chrome CYP2Cl9 [3, 7, 10, 11]. In experimental candidiasis, 
the ratio of voriconazole peak concentration and the 24-h area 
under the curve over the MIC have been identified as the best 
pharmacodynamie predictors of treatment success [ 12]. In con-
trast, no experimental data are available regarding the phar-
macodynamies of voriconazole for the treatment of aspergillosis 
or other mycoses. Sorne recent clinical observations have sug-
gested that under- and over-dosing of voriconazole may influ-
ence the efficacy and safety of therapy, respectively [ 1, 13-16]. 
Recently, experts have suggested that voriconazole trough blood 
levels should be measured after 1 week of therapy for dose 
adjustment to target values of2-6 mg/L [7]. However, the utility 
of such measurements remains debatable, given that multiple 
confounding factors may influence the outcome of infection 
and the assessment of tolerance in severely i1l patients [ 17-19]. 
This uncertainty highlights the need for additional drug ex-
posure-related efficacy and safety data in patients treated with 
voriconazole. The objective of the present observational study 
was to assess the utility of voriconazole therapeutic drug mon-
itoring (TDM). 
PATIENTS AND METHODS 
Patients. All consecutive adult patients treated with voricon-
azole at a single university hospital during the period 2004-
2006 were identified from the pharmacy records. Patients who 
received voriconazole with TDM were studied prospectively, 
and those who received voriconazole without TDM were an-
alyzed retrospectively. Treating physicians based the choice of 
voriconazole route and dose on the recommendations of the 
package insert, published guidelines, and the literature [ 1, 2, 
4, 20-22]. IFis were classified as either proven, probable, or 
possible according to definitions of the Invasive Fungal Infec-
tion Group of the European Organization for Research and 
Treatment of Cancer and Mycoses Study Group of the National 
Institute of Allergy and Infections Diseases [23]. Empirical an-
tifungal therapy was given to patients with persistent febrile 
neutropenia despite >96 h of broad-spectrum antibacterial 
therapy. Demographic data, clinical characteristics, diagnosis of 
IFI, and response to or experience of adverse events associated 
with voriconazole therapy were recorded. 
Response of infection to antifungal therapy. The assess-
ment of response to voriconazole therapy as partial or complete 
was based on clinical (fever, signs and symptoms of infection, 
and inflammatory markers) and radiological (CT or MRI find-
ings) improvement or resolution and on proven or presumed 
eradication of the fungal pathogen [ 6]. Lack of response to 
voriconazole therapy was defined by persistent IFI after > 14 
days of treatment or by progressing IFI ( clinical and radiological 
progression, persistently positive culture results, or death due 
to IFI) after >7 days of treatment. 
Safety of antifungal therapy. The type and severity of se-
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vere adverse events and their causal relationship with voricon-
azole therapy were defined according to the criteria of the Na-
tional Cancer Institute [24]. 
Measurement of voriconazole blood levels. Voriconazole 
trough blood levels were studied in citrated plasma by validated 
high-pressure liquid chromatography (analytical range, 0.125-
25 mg/L) [25, 26]. Voriconazole trough levels were measured 
because of the lack of clinical data on other pharmacodynamie 
parameters that might better predict the efficacy and safety of 
therapy and because routine blood sampling just preceding the 
next voriconazole dose is practical and reliable for intrapatient 
and interpatient comparisons. The therapeutic interval for vor-
iconazole troughs was 1-5.5 mg/L [l, 8, 13, 15, 27]. The choice 
of the 1-mg/L cutoff value had been based on in vitro suscep-
tibility data (MIC90, 0.5-1 mg/L for the majority of fungal 
pathogens), considering that only the free-circulating fraction 
of voriconazole (i.e., 40%-50%) is microbiologically active and 
available for penetration in infected organs [ 3, 8, 28, 29]. The 
upper cutoff value was based on data reported for patients who 
experienced adverse events [l, 13, 14, 30]. The following vor-
iconazole therapy modifications were proposed: (1) a 50% in-
crease in daily dose in patients with trough levels ~ 1 mg/L and 
lack of response to therapy, as recommended in the package 
insert, and (2) discontinuation of therapy in patients with 
trough levels >5.5 mg/L plus/minus adverse events probably 
related to overdosing. 
Statistical analysis. Proportions were compared by the x2 
test or Fisher's exact test, as appropriate. Continuons variables 
were compared by the nonparametric Mann-Whitney U test 
or Kruskal-Wallis test, as appropriate. Statistical significance 
was defined by a 2-sided P value <.05. The Spearman method 
was used to study the correlation of 2 variables. A logistic 
regression analysis (Stata software, version 8.2; Stata) was per-
formed to assess whether the log-transformed voriconazole 
trough concentration is a significant predictor of response to 
therapy (coded as success or lack of response) or safety (coded 
as absence or presence of severe toxicity). 
RESULTS 
Patients. Among 96 adult patients treated with voriconazole 
during the study period, 52 had TDM. All patients with TDM 
were white; 51 (98%) of 52 were inpatients. The most frequent 
underlying condition was acute myeloid leukemia with neu-
tropenia following myeloablative chemotherapy. Patients de-
mographic data and clinical characteristics are summarized in 
table 1. 
·· Data were analyzed retrospectively for 39 (89%) of 44 pa-
tients without voriconazole TDM; of these patients, 13 (33%) 
were neutropenic, 21 (54%) had another type of immunosup-
pression, and 5 (13%) had no underlying condition. 
Voriconazole therapy. A total of 2388 days of voriconazole 
Table 1. Demographic and clinical characteristics, invasive fungal infec-
tions, and voriconazole therapy in 52 patients with therapeutic drug 
monitoring. 
Variable 
Demographic data 
Age, median years (range) 
Sex, male:female 
Underlying condition 
Hematological malignancy, neutropenia <0.5 g/L 
Solid-organ transplantation 
Abdominal surgery 
Chronic liver disease 
Other conditiona 
None 
Fungal infection 
Proven or probable invasive aspergillosisb 
Lung 
Sinusc 
Disseminatedd 
lntra-abdominal 
Proven or probable invasive candidiasis0 
Bloodstream 
Hepatosplenic 
Bo ne 
Other proven invasive fun gal infection (Pseudal/escheria bovdii and 
Paecifomvces species): bone 
Possible invasive fungal infection: lung 
Persistent lever during neutropenia 
Voriconazole therapy 
First line 
Second line 
Failure of first-line therapy 
lntolerance to first·line therapy 
Switch from intravenous to oral therapy 
Route of administration 
lntravenous 
Switch from intravenous to oral therapy 
Oral 
Voriconazole daily dose, median mg/kg/day (range) 
Loading dose (oral or intravenous) 
Maintenance dose 
lntravenous 
Oral 
Duration of therapy, median days (range) 
Overall 
1 ntravenous 
Oral 
NOTE. Data are no. (%) of patients, unless otherwise indicated. 
Patients with 
measured 
voriconazole 
blood levels 
(n = 52) 
58.5 (23-78) 
38 (73): 14 (27) 
32 (61) 
3 (6) 
3 (6) 
3 (6) 
7 (13) 
4 (8) 
26 (50) 
19 (36) 
3 (6) 
3 (6) 
1 (2) 
8 (15) 
3 (6) 
4 (7) 
1 (2) 
2 (4) 
11 (21) 
5 (10) 
33 (64) 
19 (36) 
1 (2) 
9 (17) 
9 (17) 
40 1771 
17 (33) 
12 (23) 
12 
8 (6-11) 
6.5 (2-11)1 
50 (4-1130) 
6.5 (4-30) 
55 (5-1130) 
a Chronic lung disease (2 patients), diabetes mellitus (2 patients), HIV infection (2 pa· 
tients), and open knee fracture (1 patient). 
b Proven aspergillosis (19 patients) and probabl_e aspergillosis (7 patients). 
c With intracerebral extension (1 patient). 
d lnvolvement of lung (3 patients), sinus (2 patients), liver (2 patients), and skin (1 patient). 
e Proven candidiasis (4 patients) and probable candidiasis (4 patients). 
1 lntravenous vs. oral maintenance daily dose (P = .07). 
therapy in 52 patients with TDM were studied. Types and sites 
of IFI and data on therapy are summarized in table 1. 
Among 39 patients without voriconazole TDM, 31 (79%) 
were treated for aspergillosis (6 proven cases, 16 probable cases, 
and 9 possible cases), 2 (5%) were treated for proven candi-
diasis, and 6 (16%) were treated for persistent febrile neutro-
penia. Patients received voriconazole intravenously in 9 (23%) 
of the cases, intravenously followed by orally in 12 (31 %), and 
orally in 18 (46%). The voriconazole loading dosage was 12 
mg/kg per day, and the median maintenance dosage was 6.5 
mg/kg per day (range, 5-8 mg/kg per day). The median du-
ration of therapy was 30 days (range, 7-365 days). 
Measurements of voriconazole trough blood levels. A total 
of 181 voriconazole trough levels were measured (median num-
ber per patient, 4.5; range, 1-9). The median time interval 
between dose administration and measurement of trough levels 
was 12 h (range, 11-13 h). The first trough levels were measured 
at a median of 5 days (range, 3-46 days) after starting therapy. 
The median time elapsed between consecutive blood level mea-
surements was 7 days (range, 1-62 days). Figure 1 shows the 
trough levels in patients receiving different voriconazole daily 
doses. A large intradose variability in voriconazole levels was 
observed. No significant difference was found among trough 
levels at different daily doses, nor was any correlation between 
daily doses and trough levels observed (r 2 = 0.07). During 
therapy with identical daily doses in 13 patients, the intrain-
dividual variability of trough levels was substantial. In 5 pa-
tients, levels increased (median increase, 61 %; range, 22%-
125%; 1 patient had an increase >100%); in 8 patients, levels 
decreased (median decrease, 52%; range, 42%-84%; 4 patients 
had a decrease >50%). 
Response of infection to voriconazole therapy. At the time 
of clinical assessment, voriconazole trough levels were ~ 1 mg/ 
L in 13 cases (25%) and >1 mg/L in 39 cases (75%). A sig-
nificantly higher proportion of patients with levels ~ 1 mg/L 
received oral voriconazole. Lack of response to therapy was 
more frequently observed in patients with levels ~ 1 mg/L 
( 46%) than in th ose with levels > 1 mg/L (12%; P = .02) (table 
2). Among patients with levels ~ 1 mg/L, the characteristics of 
those with lack of response (6 patients) and those responding 
to therapy (7 patients) were compared. Immunosuppression 
was present in 5 (83%) of 6 and 5 (71%) of 8 patients, re-
spectively. Aspergillosis was diagnosed in 5 patients (83%; 3 
patients received a diagnosis of extrapulmonary aspergillosis) 
and 4 patients (57%; no patients received a diagnosis of ex-
trapulmonary aspergillosis), respectively. The clinical course of 
6 patients with persistence or progression of IFI and voricon-
azole levels ~ 1 mg/L is shown in table 3. In all 6 patients, IFI 
responded after an increase in voriconazole doses (no antifun-
gal agent was added to the treatment regimen). Neutropenia 
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Figure 1. Relationship between voriconazole dosage and voriconazole 
trough blood level. Each point represents a single blood level measure-
ment. Numbers of measurements for each daily dose are reported. Hor-
izontal bars represent median values (the numerical values are reported 
on the right of the horizontal bar for each group). Voriconazole dosages 
have been rounded to the nearest unit. 
resolved in 2 patients (after clinical response ofIFI in 1 patient); 
immunosuppression persisted in 3 patients (in 1 patient re-
ceiving azathioprine and/or corticosteroids, 1 patient with 
AIDS, and 1 patient with liver cirrhosis), and 1 patient was not 
immunocompromised. 
Among the 5 patients with voriconazole levels >l mg/L (me-
dian voriconazole level, 4.1 mg/L; range, 2.4-9 mg/L) and lack 
of response to therapy, 1 had probable invasive candidiasis, 1 
had probable invasive aspergillosis, 2 had possible IFI, and 1 
had breakthrough PCR-proven zygomycosis. In 4 cases, treat-
ment was switched to a salvage regimen ( 1 patient received 
caspofungin, 2 received liposomal amphotericin B, and 1 re-
ceived a combination of both agents) after a median of 9 days 
of voriconazole therapy (range, 4-21 days). Three patients had 
complete resolution of IFI (median duration of follow-up, 60 
days; range, 45-60 days), and 2 patients <lied due to IFI (after 
5 and 7 days, respectively). 
The logistic regression analysis indicated that the log-trans-
formed voriconazole trough level is a significant predictor of 
response to therapy: a 2-fold increase in blood level is associated 
with an OR for success of 1.8 (95% CI, 1.1-3.l; P = .03). The 
logistic regression model indicates a 70% probability of re-
sponse at a voriconazole trough concentration of 1 mg/L (figure 
2A). 
Among the 39 patients without voriconazole TDM, 9 patients 
( 1 with proven, 5 with probable, and 3 with possible IFI) did 
riot respond to therapy (no MIC data were available). For 3 
patients, voriconazole doses were increased (2 patients re-
sponded, and there was no follow-up in 1 patient); in 2 patients, 
therapy was switched to a salvage regimen ( 1 patient responded, 
Table 2. Voriconazole trough blood levels and clinical response to antifungal therapy. 
Variable 
Route of voriconazole administration 
lntravenous 
Oral 
Voriconazole dosage, median mg/kg/day {range) 
Ove ra li 
1 ntravenous 
Oral 
Response to antifungal therapy 
Voriconazole trough 
blood level 
,,;1 mg/L >1 mg/L 
{n = 13) {n = 39) 
4 (31) 24 (61) 
9 (69) 15 (39) 
7 (2.5-9) 8 (2-11) 
7.5 (7-8) 8 (6-11) 
6 (2.5-9) 7 {2-11) 
p 
.05 
NS 
NS 
NS 
lnterval between start of voriconazle therapy and assessment, median days {range) 
Treatment success 
21 (10-120) 17.5 (10-180) NS 
Ove ra li 
Complete response 
Partial response 
Lack of response 
Persistence 
Progression 
Breakthrough IFI 
7 {54)a 
5 
2 
6 (46) 
3 (23) 
3 (23) 
0 (0) 
34 (88) .02 
27 
7 
5 (12) 
0 (0) 
4 (10) 
1 (2) 
NOTE. Data are no. (%)of patients, unless otherwise indicated. NS, not significant. 
a ln 1 patient, comedication with rifampin resulted in low voriconazole blood levels. 
and 1 patient <lied of refractory IFI); and in 4 patients, therapy 
remained unchanged (ail 4 patients <lied of refractory IFI). 
Safety of voriconazole therapy. Voriconazole trough lev-
els were ~5.5 mg/Lin 36 patients (69%) and >5.5 mg/Lin 
16 patients (31%) (table 4). The majority of patients with 
voriconazole levels >5.5 mg/L received voriconazole intra-
venously, and a significant proportion of these patients re-
ceived omeprazole comedication. Pive serions neurological 
adverse events (National Cancer Institute grade 3) were ob-
served in patients with voriconazole levels >5.5 mg/L (31 % ), 
compared with none among patients with levels ~5.5 mg/L 
(0%; P = .002). The clinical characteristics and the course of 
adverse events in these patients are summarized in table 5. 
When patients with trough levels >5.5 mg/L with and without 
toxicity were compared, voriconazole daily doses, route of 
administration, and blood levels were similar (data not 
shown). Absence of other causes and prompt and complete 
neurological recovery after therapy discontinuation suggest 
the probable relationship between these encephalopathies and 
voriconazole overdosing. The logistic regression analysis con-
firmed a significant association between voriconazole trough 
concentrations and neurotoxicity: the OR for severe toxicity 
after a 2-fold increase of voriconazole levels in blood was 284 
(95% CI, 0.96-84,407; P = .05). The estimated probability of 
neurotoxicity at voriconazole trough levels of 5.5 mg/L and 
8 mg/L was 15% and 90%, respectively (figure 2B). 
A severe cholestasic hepatopathy ( defined as 10 times the 
baseline or 3 times the baseline, if the baseline was >3 times 
the upper limit of normal) occurred in 6 patients (2 with pre-
existing hepatopathy). These events were observed in 8% of 
patients with voriconazole levels ~5.5 mg/L and in 19% of 
those with levels >5.5 mg/L (the difference was not statistically 
significant). Although this toxicity was possibly or probably 
related to voriconazole, no correlation was found between vor-
iconazole trough levels and alkaline phosphatase (r 2 = 0.01) 
or -y-glutamyl transpeptidase (r 2 = 0.01 ). Voriconazole dose 
was reduced by 50% in 4 cases: cholestatic parameters remained 
> 10 times the upper limit of normal in 2 patients and decreased 
to 5 times the upper limit of normal in 2 patients. After dis-
continuation ofvoriconazole, cholestasis decreased to 3-5 times 
the upper limit of normal in ail patients within a median of 
20 days (range, 10-30 days). In 2 patients who had long-term 
follow-up (10 and 12 months), the liver parameters remained 
elevated despite the absence of a pre-existing hepatopathy. The 
logistic regression analysis failed to demonstrate a significant 
association between voriconazole levels and hepatotoxicity; the 
OR for hepatotoxicity of a 2-fold increase in voriconazole levels 
was 1.4 (95% CI, 0.7-3). 
Among 39 patients without voriconazole TDM, 7 (18%) 
experienced serions adverse events possibly related to therapy 
(2 of which were neurological and 5 of which were hepatic). 
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Table 3. Characteristics and clinical course of patients with voriconazole (Vor) trough blood levels ""1 mg/l and lack of response to antifungal therapy. 
Duration of 
therapy at Time to 
time of first Var 
assessment Var trough Assessment of contrai Var trough Final assessment of 
Age, Weight, Underlying disease/ Invasive Var daily dose, of response, blood level, response to Modification Var daily blood level, blood levels response, days of 
Patient Sex years kg 1mmunosuppress1on fungal infection route days mg/L Var therapy dose, route days in follow-up, mg/L follow-up 
M 58 77 Acute leukemia/ Probable pulmonary 5 mg/kg/day (2 x 24 <0.2 POi: persistent fever and in- lncrease to 8 mg/kg/ 10 1.1, 2.1, 1.7 Complete response, 
neutropenia aspergillosis 200 mg), oral flammatory syndrome, RP of day (2 x 300 mg), 75 
initial focus, and new contro- oral 
lateral lesion (on CTI 
65 56 Crohn disease, sur- Proven peritoneal as- 7 mg/kg/day 12 x 20 0.7 Pl alter surgery: persistent te- 1 ncrease to 11 mg/kg/ 2, 2.4 Complete response, 
gery for taxie me- pergillosis:Aspergil- 200 mg), oral ver and inflammatory syn- day 12 x 300 mg), 60 
gacolon/corticoste- lus fumigatus; MIC salvage therapy drame, persistence of As- oral 
raids and of Var, 0.25 mg/L alter failure of pergilfus species in 
azathioprine fluconazole peritoneal fluid 
therapy 
3 M 68 45.5 HIV infection with Proven pulmonary as- 9 mg/kg/day (2 x 14 0.9 POi: persistent lever, cough lncrease to 13 mg/kg/ 7 2.9, 2.9, 3.5 Complete response, 
AIDS pergillosis: A. fumi- 200 mg), oral and inflammatory syndrome, day 12 x 300 mg), 90 
gatus; MIC of Var, (concomitant RP of initial locus (on CTI oral 
0.5 mg/L lopinavir and ri-
tonavir therapy) 
4 M 64 62 Hodgkin lymphoma/ Probable hepatos- 6.5 mg/kg/day (2 34 0.7 Pl: persistent fever and inflam- lncrease to 10 mg/kg/ 7 2.3, 2.0, 2.1 Complete response, 
neutropenia plenic candîdiasis X 200 mg), matory syndrome, no radio- day (2 x 300 mg), 65 
intravenous logical change (on CTI intravenous 
5 M 70 81 Alcoholic liver Proven sinus aspergil- 2.5 mg/kg/day (2 13 Pl alter surgery: persistent te- lncrease to 3.5 mg/ 5 2.8, 1.6, 2.3 Complete response, 
cirrhosis losis with cerebral X 100 mg), ver and symptoms (nasal kg/day (2 X 150 50 
extension: Aspergil- oral congestion, facial pain), no mg), oral 
lus ffavus; MIC of radiological change (on MRll 
Var, 0.25 mg/L 
6 61 63 None Proven sinus aspergil- 6.5 mg/kg/day (2 22 <0.2 POi alter surgery: RP, eth- lncrease to 9 mg/kg/ 7 2.7, 3.1, 2.8, 3 Complete response, 
losis: A fumigatus; X 200 mg), moidal focus with extension day 12 x 300 mg), 180 
MIC of Var, 0.25 1ntravenous to skull bas1s (on MRll intravenous 
mg/L 
NOTE. Pl, persistent infection; POi, progression of infection; RP, radiological progression. 
Table 4. Voriconazole (Vor) trough blood levels and safety of antifungal therapy. 
Vor trough blood level 
~5.5 mg/L >5.5 mg/L 
Variable (n = 36) (n = 16) p 
Vor route .07 
1 ntravenous 15 (42) 13 (81) 
Oral 21 (58) 3 (19) 
Vor dosage, median mg/kg/day (range) 
Ove ra li 7 (2-11) 8 (6-11) .13 
1 ntravenous 7.5 (6-10) 8 (6-11) NS 
Oral 6 (2-11) 7 (6-8) NS 
Serious adverse event 
Encephalopathy 
Incidence 0 5 (31) .002 
lnterval after start of Vor, days (range) NA 9 (5-30) 8 
Cholestatic hepatopathy 
Incidence 3 (8) 3 (19) NS 
lnterval after start of Vor, days (range) 50 (5-150) 13 (6-20) NS 
Concomitant therapy 
Omeprazole 6 (17) 7 (44) .04 
Tacrolimus 0 1 (6) NS 
NOTE. Data are no. (%} of patients, unless otherwise indicated. 
a The time interval elapsed between start of Vor therapy and documentation of Vor blood levels >5.5 
mg/L in patients without encephalopathy was a median of 5 days (range, 2-7 days}; P = .04, vs. time 
interval in patients with encephalopathy. 
The 2 patients with neurological symptoms completely recov-
ered after discontinuation of voriconazole. 
DISCUSSION 
We report the experience with voriconazole TDM during 2388 
treatment-days in 52 white adult patients. A large variability in 
voriconazole trough levels was observed: voriconazole trough 
levels were ~ 1 mg/Lin 13 (25%) of the patients (the majority 
of whom were receiving oral therapy) and >5.5 mg/L in 16 
(31 %) (the majority of whom were receiving intravenous ther-
apy). This observation is consistent with previous reports [ 16, 
27, 31]. Intravenous daily doses were higher than oral daily 
doses. Confounding factors-such as drug-drug interactions, 
liver disease, and polymorphism of cytochrome CYP2Cl9-
may have influenced voriconazole metabolism in some indi-
viduals. Among white individuals, 26% of heterozygous exten-
sive metabolizers (who experienced 2-fold voriconazole 
exposure, compared with homozygous extensive metabolizers) 
and 2% of homozygous poor metabolizers (who experienced 
4-fold exposure) have been described [ 10, 27]. CYP2Cl9 ge-
notype was not determined in the present study. 
Persistence or progression of IFI was observed in a signifi-
cantly higher proportion of patients with voriconazole trough 
concentrations ~ 1 mg/L, compared with patients with trough 
concentrations > 1 mg/L. The association between trough levels 
and response to antifungal therapy was confirmed in a logistic 
regression model. No fungal in vitro resistance was documented 
as a cause of treatment failure. No difference in immunosup-
pressive conditions was found. In all cases involving a lack of 
response at low voriconazole levels, an increase in voriconazole 
doses resulting in levels > 1 mg/L was successful. The choice of 
the 1-mg/L cutoff value for voriconazole trough concentrations 
had been based on (1) in vitro susceptibility data (MIC90, 0.5-
1 mg/L for the majority of pathogenic fungi), (2) the fact that 
only the free-circulating fraction of voriconazole ( 40%-50%) 
is microbiologically active and penetrates infected tissues, (3) 
the fact that blood sampling just preceding the next voricon-
azole dose is practical and reliable for intrapatient and inter-
patient comparisons, and ( 4) the lack of clinical data on other 
pharmacodynamie parameters that might better predict efficacy 
and safety [3, 8, 28, 29]. Patients with voriconazole levels ~ 1 
mg/L received oral treatment more frequently than did those 
with levels > 1 mg/L. Variability in oral bioavailability associated 
with meals and hepatic first-pass effect might have contributed 
to lower exposure [ 1, 13, 27]. De gradation of oral voriconazole 
by intestinal cytochrome enzymes may contribute to impaired 
drug absorption: the reversing effect on this phenomenon of 
grapefruit juice has been associated with improved bioavaila-
bility in mice [32]. No drug-drug interaction could be identified 
in patients with voriconazole underexposure. In 2 patients, the 
recommended oral dosage not adjusted for body weight (200 
mg twice per day) was lower than the intravenous dosage (4 
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Table 5. Characteristics of and clinical course in patients with voriconazole (Vor) trough blood levels >5.5 mg/l and serious neurological adverse events. 
Assessment of 
Duration of se nous 
therapy at adverse events; Time to Var 
time of Var causality of Var; follow-up trough 
Underlying Var occurrence rrough National Var blood level blood level 
Age, Weight, disease/invasive daily dose, Concomitant of adverse blood level, Cancer Modification to alter stopping during follow-up, Final clinical assessment 
Patient Sex years kg fungal infection route therapy event, days mg/L lnstitute grade Var therapy Var, days mg/L (days of follow-up} 
35 54 Lung transplantation/ 7.5 mg/kg/day (2 Tacrolimus 16 6.9 Confusion, agitation, my- Discontinuation NA NA Complete resolution 15 
probable pulmonary x 200 mg}, oral oclonies, EEG pattern of days after discontinuation 
aspergillosis taxie encephalopathy (nor- of Var}, prolongation of 
mal CT findings}; probable; hospital stay 
grade 3 (concomitant se-
vere cholestasîs) 
M 61 100 Acute leukemia/prob- 8 mg/kg/day (2 x Omeprazole 30 11.2 Confusion, extrapyramidal Decrease dosage 4.3 Complete resolution (5 
able pulmonary 400 mg}, signs, myoclonies, EEG ta 6 mg/kg/day days after discontinuation 
aspergillosis intravenous pattern of taxie encepha- (2 X 300 mg}, of Var}, prolongation of 
lopathy (normal CT find- then 3 (2 x hospital stay 
ings}; probable; grade 3 150 mg}, then 
discontinuation 
3 M 59 80 Acute leukemia/ 8 mg/kg/day (2 x Omeprazole 5.9 Confusion, worsening halluci- Discontinuation 1.6 Complete resolution 13 
proven pulmonary 320 mg}, nations; probable; grade 3 days atter discontinuation 
aspergillosis intravenous of Var}; rechallenge with 
a lower dose of Var was 
well tolerated 
4 M 66 57 Acute leukemia/ 7 mg/kg/day 12 x Omeprazole 5.6 Persistent vîsual and auditive Decrease dosage 3 Complete resolution (4 
proven pulmonary 200 mg), hallucinations; probable; ta 5 mg/kg/day days after discontînuation 
aspergillosis 1ntravenous grade 3 (concomitant he- (2 X 150 mg), of Var} 
patic serious adverse then 
event} discontinuation 
M 31 74 Acute leukemia/possi- 8 mg/kg/day 12 x None 3 9 Confusion, persistent visual Discontinuation NA NA Complete resolution (2 
ble pulmonary inva- 300 mg}, hallucinations; probable; days after discontinuation 
slve fungal infection intravenous grade 3 of Vorl 
NOTE. NA, not available. 
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Figure 2. Voriconazole trough blood levels and logistic regression 
model for response to antifungal therapy (A) and for neurotoxicity (8). 
The symbols represent the voriconazole levels observed in each individual 
patient with treatment success (top) or lack of response to therapy 
(bottom) and with (top) or without (bottom) signs of neurological toxicity. 
The continuous line represents the logistic regression model predicting 
the probability of response to antifungal therapy (A) or neurotoxicity (B) 
as a function of the voriconazole trough blood concentration. The vertical 
dotted lines indicate the proposed 1-5.5-mg/L therapeutic interval of 
voriconazole. 
mg/kg twice per day). Our data confirm and extend previous 
observations that low voriconazole levels may impair the re-
sponse of IFI to therapy. The US Food and Drug Administra-
tion's voriconazole briefing document reports a pharmacoki-
netic/pharmacodynamic analysis involving 280 cases of proven 
or probable IFI that suggests a trend to higher success rates in 
patients with mean voriconazole levels >0.5 mg/L (136 [56%] 
of 245 patients), compared with patients with levels <0.5 mg/ 
L (16 [46%] of 35 patients; OR, 1.5; 95% CI, 0.6-3.4) [27]. In 
an open-label, multicenter trial of voriconazole for first-line or 
salvage therapy in 116 patients with aspergillosis, 6 treatment 
failures among 11 patients with mean voriconazole levels <0.5 
mg/L were observed [ l]. A relationship between voriconazole 
levels randomly measured during the dosing interval and treat-
ment success was described in 28 patients with IFI: there was 
a 100% treatment response rate in patients with voriconazole 
levels >2 mg/L and a 56% response rate in patients with vor-
iconazole levels <2 mg/L [ 15]. Among a group of 8 critically 
ill patients who received voriconazole via a nasogastric tube, 2 
treatment failures that were possibly associated with low blood 
levels of voriconazole were observed [33]. Six breakthrough 
IFis occurred during voriconazole prophylaxis in a group of 
43 allogeneic hematopoietic stem cell transplant recipients with 
voriconazole trough concentrations <2 mg/L, and none oc-
curred in a group of 24 such patients with voriconazole trough 
concentrations >2 mg/L [34]. These data are consistent with 
the exposure-response relationship recently described for po-
saconazole, another new-generation triazole [35]. 
Safety issues were also found to be associated with the var-
iability of voriconazole blood levels. We observed a taxie en-
cephalopathy in one-third of patients with trough levels >5.5 
mg/L after > 1 week of therapy. The association between over-
dosing and neurotoxicity was confirmed in a logistic regression 
model. These persistent or worsening neurological manifesta-
tions, which differed from transient and spontaneously resolv-
ing disturbances of light perception reported in 20%-25% of 
patients, promptly resolved after discontinuation of therapy. 
Moreover, in patients with high levels of voriconazole and no 
neurological symptoms or signs, prompt dose reduction or dis-
continuation of voriconazole might have prevented toxicity by 
limiting the duration of overexposure. The majority of patients 
with blood levels >5.5 mg/L were treated intravenously, with a 
trend towards higher daily doses. Drug-drug interactions, in 
particular with omeprazole, may have played a role in vori-
conazole overdosing [27, 36, 37]. The severe cholestasis that 
developed during therapy might also have contributed to vor-
iconazole accumulation. Two studies have described visual hal-
lucinations in 4% of cases and encephalopathy in 1 % of cases 
during voriconazole therapy. However, no data on voriconazole 
levels were reported [2, 22]. Another trial reported voriconazole 
trough levels >10 mg/Lin 6 (5%) of 116 patients, all ofwhom 
required discontinuation of therapy: in 3 (50%) of 6 patients, 
toxicity possibly related to overdosing was described [ l, 13, 17]. 
Other investigators reported a significant association between 
visual adverse events and voriconazole levels; the rate of such 
events was 18% among patients with trough concentrations <l 
mg/L and 31 % among those with trough concentrations >9 
mg/L [38]. Six neurological adverse events were described 
among a group of 28 patients; the hazard ratio was 2.3 (95% 
CI, 1.4-3.6) per 0.1 mg/L increase in voriconazole trough level 
[ 14]. A patient with li ver cirrhosis treated with voriconazole ( 4 
mg/kg per day) and pantoprazole developed coma while the 
voriconazoie trough level was 13.9 mg/L and then rapidly re-
Cbvered when the voriconazole level decreased to <10 mg/L 
after therapy discontinuation [30]. 
Abnormal liver fonction test results have been reported in 
1%-10% of patients receivingvoriconazole [22, 27, 39]. In our 
study, severe hepatic toxicity occurred independently of vori-
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conazole levels. This finding confirms other observations, which 
reported only a weak correlation, if any, between voriconazole 
exposure and severity ofhepatotoxicity [14, 16, 18, 27, 31, 38]. 
The lack of a prospective study design with systematic vor-
iconazole TDM at fixed time points is a limitation of the present 
study. However, similar clinical observations in patients without 
TDM suggest that the reported experiences are representative 
of individuals receiving voriconazole. No IFI with a voricon-
azole MIC of 1-4 mg/L was documented. In patients with such 
infections, individualized dose adjustments targeting voricon-
azole trough levels exceeding these values may be required [ 3]. 
In conclusion, the present study shows the importance of 
voriconazole TDM in severely ill patients with invasive mycoses 
[7, 17]. Multiple intrinsic and extrinsic factors may unpre-
dictably influence voriconazole pharmacokinetics. Because it is 
difficult to clinically identify individuals with inappropriate ex-
posure, dose adjustment after documentation of low or high 
voriconazole levels is critical if infection is not responding to 
treatment or if toxicity is suspected. Moreover, detection of 
voriconazole trough levels outside the therapeutic interval of 
1-5.5 mg/L during the first week of therapy may prevent treat-
ment failures and neurological toxicity. Prospective trials in-
cluding voriconazole TDM are needed. 
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